Page last updated: 2024-09-02

idarubicinol and Acute Disease

idarubicinol has been researched along with Acute Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boezeman, J; de Witte, T; Haanen, C; Linssen, P; Minderman, H; van der Lely, N; Wessels, J1
Paul, C; Sundman-Engberg, B; Tidefelt, U1
Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M1
de Witte, T; Linssen, P; Masereeuw, R; Muus, P; Raymakers, R; Smeets, M; Vierwinden, G1

Trials

1 trial(s) available for idarubicinol and Acute Disease

ArticleYear
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
    Leukemia, 1996, Volume: 10, Issue:4

    Topics: Acute Disease; Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Idarubicin; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Middle Aged

1996

Other Studies

3 other study(ies) available for idarubicinol and Acute Disease

ArticleYear
Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
    Leukemia, 1994, Volume: 8, Issue:3

    Topics: Acute Disease; Antineoplastic Agents; Cell Division; Daunorubicin; Doxorubicin; Granulocytes; Hematopoietic Stem Cells; Humans; Idarubicin; Leukemia, Myeloid; Macrophages; Tumor Stem Cell Assay

1994
Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
    Leukemia research, 1994, Volume: 18, Issue:4

    Topics: Acute Disease; Aged; Daunorubicin; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged

1994
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
    Leukemia, 2001, Volume: 15, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Daunorubicin; Female; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence

2001